Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $53.6667.

Several equities analysts have commented on CAPR shares. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. B. Riley Financial upped their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Roth Mkm reaffirmed a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th. LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 50,000 shares of company stock worth $1,551,658 in the last 90 days. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $43,000. KBC Group NV purchased a new stake in Capricor Therapeutics in the 1st quarter valued at $44,000. GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics during the 4th quarter worth $59,000. Finally, Tower Research Capital LLC TRC grew its position in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

NASDAQ:CAPR opened at $23.21 on Monday. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The firm has a market capitalization of $1.34 billion, a PE ratio of -10.00 and a beta of 0.42. The business’s fifty day moving average price is $28.87 and its 200 day moving average price is $28.28.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities analysts anticipate that Capricor Therapeutics will post -0.49 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.